Sign In
Buy OPORF
$0.350
+0 (+0%)
At Close: Jun 03, 2026
hVIVO's first-half trading update shows steady progress despite sector headwinds
10:16am, Tuesday, 22'nd Jul 2025
hVIVO PLC (AIM:HVO) has reported revenues of £24.2 million for the first half of 2025, broadly in line with expectations for full-year revenues of £47 million, as the company continues to diversify
hVIVO revenues dip but acquisitions bolster outlook amid industry slowdown
02:37am, Tuesday, 22'nd Jul 2025
hVIVO PLC (AIM:HVO), the London-listed clinical research group, said it is trading in line with previous market expectations, as it told investors its acquisition strategy is bearing fruit. The group,
hVIVO reports successful role in flu prevention trial
02:36am, Monday, 30'th Jun 2025
hVIVO PLC (AIM:HVO) said it had completed a key role in a large-scale clinical trial of a new flu prevention drug that showed strong results, marking another milestone for the specialist research org
hVIVO shares rise 23% as CEO and CFO buy in after contract setbacks
06:25am, Monday, 02'nd Jun 2025
Shares in hVIVO PLC (AIM:HVO) rose 23% on Monday after the company's top two executives bought a combined 1.8 million shares, a move Peel Hunt said would offer reassurance to investors following rece
Brokers back hVIVO's long-term vision
11:19am, Friday, 30'th May 2025
Shore Capital has maintained a 'buy' stance on hVIVO PLC (AIM:HVO), underscoring the company's potential despite its contract setback announced earlier Friday. The investment case rests on hVIVO's amb
hVIVO flags contract setback and record order book
03:01am, Friday, 30'th May 2025
hVIVO PLC (AIM:HVO) has reported the cancellation of one trial and the postponement of another, but said its pipeline of new business has reached record levels, with several large contracts in late-s
hVIVO: Numbers starting to stack up, says broker
10:51am, Tuesday, 27'th May 2025
A contract-driven business always carries a degree of lumpiness. For hVIVO PLC (AIM:HVO), the question now is whether that volatility can be managed convincingly enough to meet this year's revenue gui
hVIVO offers a 'compelling opportunity', broker says
09:02am, Monday, 12'th May 2025
For investors seeking differentiated exposure to innovation in the drug development sector, Cavendish believes hVIVO PLC (AIM:HVO) offers a 'compelling' route in. The company runs human challenge tr
hVIVO appoints interim chair and says goodbye to long-serving NED
02:31am, Monday, 12'th May 2025
Clinical trials group hVIVO PLC (AIM:HVO) will see two senior board members step down at its annual general meeting next month, including its long-serving chair Cathal Friel and non-executive directo
hVIVO CEO on £73m target and expansion strategy - ICYMI
08:36am, Friday, 11'th Apr 2025
hVIVO PLC (AIM:HVO) chief executive Yamin ‘Mo' Khan talked with Proactive about the company's record-breaking financial performance in 2024, operational milestones and strategic outlook. Khan report
Trio of City analysts see substantial upside for hVIVO
10:52am, Thursday, 10'th Apr 2025
A trio of City analysts reacted to upbeat results from hVIVO PLC (AIM:HVO), with all three pointing to the upside. hVIVO earlier today delivered record earnings and provided a confident assessment of
hVIVO provides confident assessment of prospects after posting record earnings
04:06am, Thursday, 10'th Apr 2025
hVIVO PLC (AIM:HVO) has delivered record earnings and provided a confident assessment of the year ahead as demand grows for its specialist infectious disease trials and the company expands into new
hVIVO a world leader in an expanding niche quietly making progress
05:56am, Friday, 21'st Mar 2025
Few companies can claim to be world leaders in their niche, but hVIVO PLC (AIM:HVO) comfortably falls into that category. The business, which specialises in human challenge trials, has carved out a s
hVIVO seriously undervalued, says broker as it initiates with a 'buy' call
06:07am, Monday, 10'th Mar 2025
Shore Capital has initiated coverage on hVIVO PLC (AIM:HVO) with a bullish outlook, setting a 'fair value' target of 35p per share — more than double its current trading price of 17.22p. The firm b
Mo Khan on hVIVO's Cryostore acquisition - ICYMI
10:36am, Friday, 28'th Feb 2025
hVIVO PLC (AIM:HVO) chief executive Yamin ‘Mo' Khan talked with Proactive about the company's strategic acquisition of Cryostore, a specialist in temperature-controlled storage solutions for biologi
